# Uniting Laboratory Science, Policy and Implementation

**Peter Lamptey** 

Distinguished Scientist/President Emeritus, FHI360 Prof. of Non-communicable Diseases, LSHTM



#### Outline

- Introduction: The Lancet Commission
- Role of FHI360 in Laboratory Medicine in SSA
- Evolving disease burdens in LMIC
- Public Health response in NCD
- Future role of the laboratory in NCD
- Conclusions



### Introduction

#### The Lancet Commission on the Future Health of Africa



#### Balancing the Development Agenda in Africa

- Challenging developmental issues poverty, population growth, rapid urbanization
- Growing economies & economic disparities
- Unfinished health agenda infectious diseases, nutrition, MCH, SR/H, diarrhea etc.
- Civil conflicts Sudan, CAR, Somalia
- Emerging new burdens
  - Newer diseases Ebola
  - Climate change, environmental degradation
- NCD diseases of the present and future



### FHI360 Integrated Development Approaches

FHI360 has strengthened laboratory services in Africa to support research and programs in order to influence policy



FHI 360 works with laboratories that serve public and private health programs as well as research activities in Africa

- Supports over 300 laboratories across the Africa region
- Supports regional laboratory services in Bangkok
- Conducted over 100 laboratory trainings across Africa
- Pioneered innovative testing services in SSA







### **THE NCD BURDEN**

#### UNITING POLICY, PROGRAMS AND LABORATORY SCIENCE FOR AN IMPROVED RESPONSE



#### Non-communicable Diseases in LMIC

We have acquired the so-called diseases of the wealthy but without the wealth



#### **NCD Epidemics in LMIC**

 80% of NCD deaths occurred in low- and middle-income countries (LMIC) in 2011 [26 Million/ 36 Million]



Source: WHO The top 10 causes of death, Fact sheet N°310, Updated July 2013

#### Total NCD death rates\*, age standardized Males, 2008



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: World Health Organization Map Production: Public Health Information and Geographic Information Systems (GIS) World Health Organization



© WHO 2011. All rights reserved.



#### Percentage of all NCD deaths\* occuring under age of 70 Males, 2008



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which here may not yet be full agreement. Data Source: World Health Organization Map Production: Public Health Information and Geographic Information Systems (GIS) World Health Organization



© WHO 2011. All rights reserved.

#### By 2030, 4 out of 5 premature NCD deaths will occur in LMIC



#### **Ghana: NCD Situation**

- Current tobacco smoking (2011)
  = 10%
- Raised blood pressure (2008) = 27.3%
- Obesity (2008) = 7.5%
- The probability of dying between ages 30 and 70 years from the four main NCDs is 20%



NCDs are estimated to account for 42% of total de

Ref: WHO. Noncommunicable diseases country profiles 2014.



#### Biological Risk Factor Assessment Highlights 2012

- Elevated blood pressure
  - **33%** of adults (18+yrs) had elevated BP
    - 42% of urban adults and 27% of rural adults had elevated BP
    - > among those in the 46-60 yrs. age group, 55% had elevated BP
- Body Mass Index
  - 33% of men and 57% of women were either overweight or obese (BMI > 25)
  - 53% of urban adults and 44% of rural adults were either overweight or obese (BMI > 25)



## What is unique about the NCD Burden?

- High prevalence in both the rich and the poor
- Often undiagnosed until late
- Chronic in nature requires treatment and monitoring for many years
- Physician & facility-based management inadequate
- High out-of- pocket costs leads to catastrophic economic consequences for many families
- High economic costs to the country
- NCD (and ageing) will devastate the health infrastructure



## Challenges to medical laboratory services

- Inadequate capacity to meet needs
- Limited accessibility/availability
- Inadequate resources to achieve international quality standards
- Cost to patient
- Long wait for results
- Current & future laboratory infrastructure inadequate to meet clinical and public health needs



### We need a paradigm shift for an adequate response

#### Diabetes as a case study: A Challenge for Policy, Laboratory Science & Implementation



#### Type 2 diabetes mellitus: The US Experience\*

- Increasing level of obesity and ageing
- 13% of US adults (25.8M) have T2DM
- 40% of these are undiagnosed in a physician-based system
- Seven year lag between onset of symptoms & diagnosis
- Additionally, 35% of US adults (79M) have prediabetes
- 93% of pre-diabetes in the US is undiagnosed
- \* John McKinley et al., NERI



- Increasing level of obesity and ageing
- Increasing level of T2DM and pre-diabetes
- Late diagnosis, poor adherence to treatment and high mortality
- Poor data on proportion of undiagnosed T2DM and pre-diabetes
- Inadequate health system with severe shortages in personnel, equipment and infrastructure
- Facility-based medical and laboratory response inadequate



#### "If you always do what you've always done, you'll always get what you've always got".

#### Advocacy for population-based screening of those at high risk of NCD



#### Criteria for Population-based Screening

Condition should be/have:

- An important health problem
- Natural history should be understood
- Latent or asymptomatic stage
- Accurate, reliable & affordable test be available
- Community-based testing preferable
- Treatment should effective & cost-effective when started early
- Timely policy and funding decisions



#### **Screening lessons learned from HIV**

- Well-established population-based screening with RDT
- Targeted screening of MARPS or key populations have been successful
- Virtual elimination of mother to child HIV transmission in many populations
- Early diagnosis and treatment of HIV disease
- Proven effectiveness and cost-effectiveness in prevention and treatment



- Licensed Chemical Sellers are private drug shops operated by non-pharmacists who are licensed to sell over-the-counter medicines
- FHI 360 trained 1207 LCS to use Rapid Diagnostic Test kits to diagnose & treat uncomplicated malaria with ACTs
- Refer serious cases of malaria and pregnant women
- Improved access to care, improve efficiency and reduced case load at health facilities
- Funded by GlaxoSmithKline







## Population-based screening & management of NCD

- Cardiovascular disease risk factors such as:
  - Hypertension
  - Cholesterol
  - Blood glucose & HbA1c
- Cervical cancer HPV immunization & screening e.g.
  VIA,
- Liver disease HBV, HCV
- Stomach cancer H. pylori
- Chronic respiratory disease asthma
- Haemoglobinopathies Sickle cell disease



### **Future Considerations**

#### The Role of Technology in the Public Health Response



#### **Technology applications**





#### Scanadu's Medical Tricorder







## The Tricorder: Science fiction or the future?

- A non-invasive portable device that senses, computes and records personal health metrics
- "Diagnose patients as well as or better than a panel of board-certified physicians"
- Allows the patient to decide when, where & how to receive care
- \$10M Qualcomm X-price by Qualcomm Foundation
- Announced in 2012 and prize to be awarded in Jan 2016
- Are we headed for a radical change in health care delivery (similar to the internet & smart phones?

#### **fhi**360

#### **FDA Approved Digital Pill**





#### The Edible Electronic Pill: Improving Adherence in NCD

- Edible electronic sensor in a pill that keeps track of medication patterns
- Sensor transmits data to a patch on the skin to external online apps.
- It determines time of ingestion, heart rate, body position and physical activity
- Data can be used to monitor and improve health behaviors and patterns
- May also be used in research to assess compliance to treatment



#### Conclusions

- Improved prevention and treatment of current and emerging disease burdens
- Population-based screening of those at high risk
- Effective technologies to revolutionize implementation and laboratory services
- Support self-management especially in NCD
- Bring back the evidence in our programs we waste resources on too many unproven interventions



#### We Need a Paradigm Shift for the Future Public Health Response

We need to shift testing from the lab & treatment from the doctor's office to the community THANK-YOU!!

